NeuExo Therapeutics

Overview

NeuExo Therapeutics is a biotechnology company focused on developing exosome-based therapeutics for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company leverages natural extracellular vesicle (exosome) delivery systems to transport therapeutic cargo—including microRNAs, proteins, and small molecules—across the blood-brain barrier to target neurons affected by neurodegeneration.

Company Information

Overview

NeuExo Therapeutics is a biotechnology company focused on developing exosome-based therapeutics for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company leverages natural extracellular vesicle (exosome) delivery systems to transport therapeutic cargo—including microRNAs, proteins, and small molecules—across the blood-brain barrier to target neurons affected by neurodegeneration.

Company Information

| Attribute | Details |
|-----------|---------|
| Headquarters | Cambridge, Massachusetts, USA |
| Founded | 2021 |
| Focus | Exosome-based therapeutics for neurodegenerative disease |
| Lead Indication | Parkinson's disease |
| Website | https://www.neuexotherapeutics.com |

Technology Platform

Exosome Engineering Platform

NeuExo has developed a proprietary platform for engineering therapeutic exosomes:

Exosome Advantages

Exosomes offer several advantages for CNS drug delivery:

• Blood-brain barrier penetration: Natural ability to cross the BBB
• Low immunogenicity: Reduced immune response compared to viral vectors
• Cellular targeting: Can be engineered to target specific neural cell types
• Cargo versatility: Can deliver proteins, RNAs, small molecules, and nucleotides
• Repeat dosing: Feasible due to favorable safety profile

Pipeline Programs

Lead Program: miR-124 Delivery for PD

NeuExo's lead program uses exosome-mediated delivery of miR-124 for Parkinson's disease:

• Mechanism: miR-124 is the most abundant miRNA in the brain and plays critical roles in neuronal survival. In PD, miR-124 expression is significantly reduced in dopaminergic neurons.
• Therapeutic rationale: Restoring miR-124 levels can promote neuronal survival, enhance autophagy and lysosomal function, and reduce neuroinflammation.
• Delivery: Exosomes provide natural delivery across the BBB to target neurons in the substantia nigra and striatum
• Stage: Preclinical development

Supporting Science

The therapeutic approach is supported by peer-reviewed research:

• Exosome-mediated delivery of miR-124 has demonstrated neuroprotection in PD models[@mirna124exosome2021]
• miR-124 targets multiple pathways relevant to PD pathogenesis including UBE2A, BAX, and SCARB2[@mirna124pd2023]
• Exosome biology provides natural mechanisms for CNS delivery[@exosomebbb2023]

Pipeline Expansion

Additional programs in development include:

| Program | Indication | Modality | Stage |
|---------|------------|----------|-------|
| miR-7 delivery | Parkinson's disease | miRNA (exosome) | Discovery |
| GDNF delivery | Parkinson's disease | Protein (exosome) | Discovery |
| Combination therapy | PD (advanced) | Multi-cargo exosome | Research |

Competitive Landscape

NeuExo operates in the emerging exosome therapeutics space for neurodegeneration:

| Company | Approach | Stage |
|---------|----------|-------|
| NeuExo Therapeutics | Exosome-miR-124 | Preclinical |
| uniQure | AAV gene therapy | Phase 1/2 |
| Voyager Therapeutics | AAV-AADC | Phase 1 |
| RNP Inc | RNA therapeutics (RNAi/ASO) | Preclinical |
| Prothelia | AAV-GBA gene therapy | Preclinical |

Strategic Advantages

Research Partnerships

NeuExo maintains collaborations with academic centers for research and validation:

• Academic partnerships with leading neuroscience research institutions
• Collaboration with exosome biology researchers
• Engagement with PD patient advocacy organizations

Future Directions

NeuExo's development strategy includes:

Cross-Links to NeuroWiki

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Exosome Therapy for Neurodegenerative Diseases](/therapeutics/exosome-therapy-neurodegeneration)
• [MicroRNA Therapy for Parkinson's Disease](/therapeutics/mirna-therapy-parkinsons)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Dopaminergic Neurons](/entities/dopaminergic-neurons)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Exosomes](/entities/exosomes)

See Also

• [Exosome Therapy](/therapeutics/exosome-therapy-neurodegeneration)
• [MicroRNA Therapy for PD](/therapeutics/mirna-therapy-parkinsons)
• [Gene Therapy for PD](/therapeutics/gene-therapy-parkinson)
• [RNAi Therapy for PD](/therapeutics/sirna-therapy-parkinsons)

External Links

• [NeuExo Therapeutics](https://www.neuexotherapeutics.com)
• [PubMed - Exosome delivery](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References